key: cord-0312738-8uzw959k
authors: Subramaniam, Saravanan; Hekman, Ryan Matthew; Jayaraman, Archana; O’Connell, Aoife Kateri; Montanaro, Paige; Blum, Benjamin; Kenney, Devin; Ericsson, Maria; Ravid, Katya; Crossland, Nicholas A; Emili, Andrew; Douam, Florian; Bosmann, Markus
title: Platelet proteome analysis reveals an early hyperactive phenotype in SARS-CoV-2-infected humanized ACE2 mice
date: 2021-08-20
journal: bioRxiv
DOI: 10.1101/2021.08.19.457020
sha: 06620c9d1d5979a47b25a8b8691dcc9fffdd0b88
doc_id: 312738
cord_uid: 8uzw959k

Coronavirus disease-2019 (COVID-19) provokes a hypercoagulable state with increased incidence of thromboembolism and mortality. Platelets are major effectors of thrombosis and hemostasis. Suitable animal models are needed to better understand COVID-19-associated coagulopathy (CAC) and underlying platelet phenotypes. Here, we assessed K18-hACE2 mice undergoing a standardized SARS-CoV-2 infection protocol to study dynamic platelet responses via mass spectrometry-based proteomics. In total, we found significant changes in >1,200 proteins. Strikingly, protein alterations occurred rapidly by 2 days post-infection (dpi) and preceded outward clinical signs of severe disease. Pathway enrichment analysis of 2dpi platelet proteomes revealed that SARS-CoV-2 infection upregulated complement-coagulation networks (F2, F12, CFH, CD55/CD59), platelet activation-adhesion-degranulation proteins (PF4, SELP, PECAM1, HRG, PLG, vWF), and chemokines (CCL8, CXCL5, CXCL12). When mice started to lose weight at 4dpi, pattern recognition receptor signaling (RIG-I/MDA5, CASP8, MAPK3), and interferon pathways (IFIT1/IFIT3, STAT1) were predominant. Interestingly, SARS-CoV-2 spike protein in the lungs was observed by immunohistochemistry, but in platelets was undetected by proteomics. Similar to patients, K18-hACE2 mice during SARS-CoV-2 infection developed progressive lymphohistiocytic interstitial pneumonia with platelet aggregates in the lungs and kidneys. In conclusion, this model recapitulates activation of coagulation, complement, and interferon responses in circulating platelets, providing valuable insight into platelet pathology during COVID-19. Key Points SARS-CoV-2-infected humanized ACE2 mice recapitulate platelet reprogramming towards activation-degranulation-aggregation. Complement/coagulation pathways are dominant in platelets at 2 days post-infection (dpi), while interferon signaling is dominant at 4dpi.

Hospitalized COVID-19 patients frequently develop coagulation abnormalities with a high risk 22 (~10-40%) of thromboembolism. 1 Elevated fibrin-degradation products are predictors of mortality 23 from COVID-19, 2 but therapeutic anticoagulation with heparin has achieved inconsistent survival 24 benefits in clinical trials. 3, 4 Hence, there remains urgent need for molecular insight into COVID- 25 19-associated coagulopathy (CAC), which shares some features with disseminated intravascular 26 coagulopathy. 5 During CAC, human platelets are activated and participate in procoagulatory-27 inflammatory responses to COVID-19. 6-8 RNA-Seq has revealed what appears to be both direct 28 and indirect effects (e.g. mediators, aberrant antibodies) of SARS-CoV-2 infection on the platelet 29 transcriptome in patients. 9-12 30 Mouse models are essential tools for drug development. 13 As platelet-fibrin thrombi characterize multi-organ thrombosis of lethal COVID-19 in humans, 15 we 47 examined mouse lungs and kidneys at two time points (2dpi and 4dpi). Histologic findings 48 included multifocal mild-to-moderate mononuclear cell infiltrates and low numbers of neutrophils 49 in peribronchiolar, perivascular, interstitial, and alveolar spaces ( Figure 1D a-c ) . SARS-CoV-2 spike 50 protein was observed in the alveolar epithelium ( Figure 1D d-f ). Although there were no occlusive 51 thrombi, we observed sporadic enhanced aggregations of CD61 + platelets in lung capillaries 52 ( Figure 1D g-i , 1E) and kidney interstitial/glomerular capillaries ( Figure 1F j-l , 1G). 14 Lung interstitial 53 capillaries within areas of viral replication/assembly sporadically contained platelet aggregates 54 (supplemental Figure 1C ) 14 . These findings suggest platelet activation and aggregation is a 55 feature of SARS-CoV-2 infection of K18-hACE2 mice already occurring before clinical decline. 56 Next, we analyzed platelet proteomes from SARS-CoV-2-infected K18-hACE2 mice at 2dpi/4dpi 57 versus mock negative controls using mass spectrometry ( Figure 2A ). Principal component 58 analysis illustrated clear differences between experimental groups (supplemental Figure 2A) . In 59 total, ~4,600 platelet proteins were identified/quantified (supplemental File 1). SARS-CoV-2 60 induced significant changes in the abundance of many platelet proteins at both 2dpi 61 (n=591↑/476↓; P ≤ .05; Figure 2B ; supplemental File 2) and 4dpi (n=163↑/195↓; P ≤ .05; Figure   62 2C; supplemental File 3) compared to uninfected controls. Interestingly, we observed altered 63 protein expression specific to 2dpi (n=376↑/470↓; P ≤ .05; Figure 2D Histidine-rich glycoprotein (HRG) is an abundant plasma protein with a multi-domain structure, 83 allowing interaction with many ligands including phospholipids, plasminogen, fibrinogen, IgG 84 antibodies, and heparan sulfate. HRG was significantly increased at 2dpi and 4dpi ( Figure 2H ). 85 HRG exerts broad antiviral activities and might help to explain platelet-mediated antiviral 86 responses during SARS-CoV-2 infection. 18 In contrast, HRG may also have deleterious effects. 87 We speculate that HRG-coated, activated platelets could adhere to inflamed endothelium via 88 heparan sulfate, which would then block antithrombin-III binding and FXa inhibition, and could 89 ultimately promote thromboembolism/microthrombi in arterioles and venules. Figure 2N ). For instance, vWF has been reported to play a critical role in COVID-19 118 pulmonary microvascular occlusion. 25 In our interactome, we noted high interconnectivity between 119 vWF, PLG, PF4, ITGB3 and MAPK3, as well as between PF4, CXCL12 and CXCL5. ReactomePA (v1.32.0), respectively. False discovery rate (FDR) was controlled using Benjamini-245 Hochberg method. All functional enrichment analyses were performed based on pathways 246 specific to Mus musculus using gene symbols. Plots were generated for GO and pathway 247 enrichment specific to significantly upregulated proteins. To understand interactions between 248 proteins in nine key processes and pathways that were enriched in either 2dpi or 4dpi data sets, 249 an interactome was constructed and visualized using the stringApp (v1.6.0) in Cytoscape (v3.8.2). 250 The network was specific to Mus musculus and included only predicted interactions with the 251 highest combined confidence score (≥0.900). We mapped the logFold change values for these 252 proteins onto the interactome. 

The tissue 186 samples were then put in propylene oxide for 1 h and infiltrated overnight in a 1:1 mixture of 187 propylene oxide and TAAB Epon

The following day the samples were embedded in fresh TAAB Epon and 189 polymerized at 60°C for 48 h. Semi-thin (0.5 μm) and ultrathin sections (50-80 nm) were cut on a 190

Ultrathin sections from those areas were picked up onto 193 formvar/carbon coated copper grids, stained with 0.2% lead citrate and examined in a JEOL 194 1200EX transmission electron microscope

Lungs were insufflated 200 with ~1.5 ml of 1% low melting point agarose (Sigma-Aldrich) diluted in 1X PBS using a 18-gauge 201 catheter placed into the trachea. Tissues were inactivated in 10% neutral buffered formalin at a 202 20:1 fixative to tissue ratio for a minimum of 72 h before removal from BSL-3 in accordance with 203 an approved institutional standard operating procedure. Tissues were subsequently processed 204 and embedded in paraffin following standard histological procedures

PBS mock animals served as 208 biologic negative controls for SARS-CoV-2 S-protein, while the absence of immunoreactivity was 209 confirmed by the occlusion of primary antibodies or use of an isotype control specific to human 210 tissues. The following antibodies were used: Mouse-SARS-CoV-2 spike protein

SARS-CoV-2 infection activates circulating platelets

Quantification 212 of both H&E and IHC stainings was performed in biological and technical triplicates

Slides were imaged on the HALO TM image analysis platform using a Mantra 2.0™ quantitative 216 pathology workstation and unmixed with InForm software version 2.4

For each mouse, 3 images of lung tissue and 3 images of kidney tissue 218 were obtained. Slides were manually annotated to adjust visualization thresholds in order to fine-219 tune visibility of markers within each sample

Classifier module within HALO was used to discern lung stroma and glass within tissue images

Quantitative outputs of CD61 + staining were obtained using the Area Quantification (AQ) module, 222 which reports total area of immunoreactivity of a specified parameter within a region of interest

For lung samples, only the regions classified 224 as lung stroma were analyzed, glass space was excluded. Values were expressed as a 225 percentage of total tissue area analyzed. AQ was performed to determine percentage of CD61 + 226 immunoreactivity in kidneys and lungs of the studied mice

Bioinformatics analysis (pathway enrichment analysis) and 233 data visualization of significant differentially expressed proteins (P value

Entrez and Ensembl IDs were mapped using biomaRt (v2.44.4) and only proteins with mapped 236

IDs were used for visualization and downstream analysis. Volcano plots were constructed using 237 SARS-CoV-2 infection activates circulating platelets

Fatal neuroinvasion of SARS-CoV-2 in K18-266 hACE2 mice is partially dependent on hACE2 expression

Target-decoy search strategy for mass spectrometry-based proteomics

SARS-CoV-2 infection activates circulating platelets 3 ethanol/water for 1 h at room temperature. The stained wells were rinsed with tap water and the 58 numbers of plaques were counted. The titer of our passage (P)-2 virus stock was 4x10 8 plaque 59 formatting units (PFU) per ml. The mice of the 7-day survival studies were intraperitoneally implanted with a radio-frequency 78 identification (RFID) temperature-monitoring microchip (Unified Information Devices, Lake Villa, 79 IL, USA) 48-72 hours prior to inoculation. An IACUC-approved clinical scoring system was used 80 to monitor disease progression and establish humane endpoints 1 . The evaluated categories were 81 body weight, general appearance, responsiveness, respiration, and neurological signs. Clinical 82 signs and body temperature were recorded once daily for the full duration of the studies.